A response I made to a PM about MDGL and NASH.

Quote:

---

I took a look at MDGL a few days ago when some douche on YMB posted it to downplay leronlimab. Their drug is a thyroid receptor antagonist which means it's main thing is burning fat. All of the fat burning drugs against NASH have done quite poorly on fibrosis so it's no wonder they didn't mention it.

The anti-inflammatory action from the fat burning drugs would come from a reduction in fat. Since the reduction in fat is limited and fat still exists there would still be inflammation occurring. What would be expected is a reduction of new fibrosis formation but new fibrosis formation nonetheless.

With leronlimab you get the fat burning from a switch from white fat to brown fat and a better energy burn from the brown fat. Somewhere way I back I think I ran into a paper that even showed a reduction in overall obesity with CCR5 blockade. Couple that with the greatest anti-inflammatory known to man and you have a pretty good combination.I took a look at MDGL a few days ago when some douche on YMB posted it to downplay leronlimab. Their drug is a thyroid receptor antagonist which means it's main thing is burning fat. All of the fat burning drugs against NASH have done quite poorly on fibrosis so it's no wonder they didn't mention it.

The anti-inflammatory action from the fat burning drugs would come from a reduction in fat. Since the reduction in fat is limited and fat still exists there would still be inflammation occurring. What would be expected is a reduction of new fibrosis formation but new fibrosis formation nonetheless.

With leronlimab you get the fat burning from a switch from white fat to brown fat and a better energy burn from the brown fat. Somewhere way I back I think I ran into a paper that even showed a reduction in overall obesity with CCR5 blockade. Couple that with the greatest anti-inflammatory known to man and you have a pretty good combination.

---